Redx Provides Progress Update on RXC007 Clinical Programme
February 9, 2023Business Services
Alderley Park, UK, 9 February 2023 Redx (AIM:REDX), the clinical-stage biotechnology company focused on discovering and developing novel, small molecule, …
Sequana Medical announces 2022 Full Year Results and 2023 Outlook
February 9, 2023Business Services
Ghent, Belgium – 09 February 2023 – Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana Medical”), a pioneer …
Availability of Sanofi’s Nexviadyme®▼(avalglucosidase alfa) provides NHS with new treatment for Pompe disease
February 8, 2023Business Services
READING, ENGLAND – Wednesday 8th February 2023. Sanofi announced today that healthcare specialists and patients living with Pompe disease will …
Scottish biotech aims to cure common cold
February 8, 2023Medical Communications
Scottish biotech company ScotBio has announced that it has seen “promising initial results” from its attempts to extract a cure …
Johnson & Johnson’s Ethicon undertakes first robot-assisted kidney stone removal
February 8, 2023Research and Development
Johnson & Johnson (J&J) medtech company, Ethicon, has announced its first robotic-assisted kidney stone removal using its Monarch platform. The …
US Department of Justice asks Third Circuit to reinstate conspiracy charges again KVK
February 8, 2023Manufacturing and Production
The US Department of Justice (DoJ) encouraged the Third Circuit to reinstate ‘conspiracy to defraud’ charges against Philadelphia-based generic drug …
Sandoz files Amgen biosimilar drug for osteoporosis
February 8, 2023Research and Development
Switzerland-based Sandoz has filed a proposed biosimilar of Amgen’s osteoporosis drug Prolia/Xgeva with the FDA. According to Sandoz, over 10 …
Cell and Gene Therapy Catapult to play significant role in establishing one of the largest life sciences campuses in Europe
February 8, 2023Business Services
London, 8th February 2023: The Cell and Gene Therapy Catapult (CGT Catapult), an independent innovation and technology organisation specialising in …
Sequana Medical announces the successful completion of pre-clinical studies with its second-generation DSR product for congestive heart failure
February 8, 2023Business Services
Ghent, Belgium – 08 February 2023 – Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana
AstraZeneca’s Forxiga approved in EU for chronic heart failure
February 7, 2023Medical Communications
AstraZeneca has announced that its drug, Forxiga, has been approved in the EU for the treatment of symptomatic chronic heart …
Genentech shares positive results from global phase 3 trials for crovalimab in PNH
February 7, 2023Medical Communications
Following the global COMMODORE 2 study, Genentech has announced positive data for crovalimab in treating patients with paroxysmal nocturnal haemoglobinuria …
4D Molecular Therapeutics’ Fabry Gene Therapy put on FDA-mandated hold
February 7, 2023Research and Development
4D Molecular Therapeutics has had its gene therapy programme 4D-310 put on clinical hold by the FDA after adverse side …
Strong sales of Basilea’s Cresemba triggers second sales milestone payment from Pfizer
February 7, 2023Sales and Marketing
Swiss commercial-stage biopharmaceutical company Basilea Pharmaceutica Ltd has announced that continued high sales of its drug Cresemba (isavuconazole) in China …
Sage Therapeutics and Biogen Announce FDA Accepts Filing of New Drug Application and Grants Priority Review of Zuranolone in the Treatment of Major Depressive Disorder and Postpartum Depression
February 7, 2023Business Services
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Sage Therapeutics, Inc. (Nasdaq: SAGE) and Biogen Inc. (Nasdaq: BIIB) announced the U.S. Food and Drug Administration (FDA) has accepted …
Oxford Science Enterprises strengthens Life Sciences investment team with appointment of Sanne de Jongh as Partner
February 7, 2023Business Services
Oxford, UK: February 7, 2023 – Oxford Science Enterprises (OSE), the independent investment company created to found, fund and build transformational businesses …
Chong Kun Dang Pharm Licenses Synaffix ADC Technology, Adds Novel ADC Candidate to Oncology Pipeline
February 6, 2023Business Services
THE NETHERLANDS and SOUTH KOREA, 6 February 2023 — Synaffix B.V., a biotechnology company focused on commercializing its clinical-stage platform …
Oxford University scientists’ AI diagnostic test accurately identifies known respiratory viruses in minutes
February 6, 2023Business Services
February 6th, 2023 – Oxford, United Kingdom – Nicolas Shiaelis and
Patients with hidradenitis suppurativa experienced sustained efficacy and symptom improvement at one year when treated with Novartis Cosentyx®
February 6, 2023Business Services
Basel, February 4, 2023 – Novartis announced today that The Lancet has published long-term data from the pivotal SUNSHINE and …
SPR Therapeutics gains FDA extended approval for pain management system
February 6, 2023Research and Development
Pain management medical device company SPR Therapeutics has obtained expanded approval from the FDA for its SPRINT Peripheral Nerve System …
Australia’s TGA approves psychedelics to treat mental health conditions
February 6, 2023Research and Development
Australia’s Therapeutic Goods Administration (TGA) has announced its approval of the use of psychedelics to treat certain mental health conditions. …
Latest content
